Evidence map›Paper›PMID 39940874›Full record

ReviewInternational journal of molecular sciences2025

Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.

Tatiana Budagova, Anna Efremova, Natalia Usman, Diana Mokrousova, Dmitry Goldshtein

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tatiana BudagovaResearch Centre for Medical Genetics, Moskvorechye Str. 1, Moscow 115522, Russia.
Anna EfremovaResearch Centre for Medical Genetics, Moskvorechye Str. 1, Moscow 115522, Russia.
Natalia UsmanDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Samory Mashela Str. 1, Moscow 117198, Russia.ORCID 0000-0002-5999-8843
Diana MokrousovaResearch Centre for Medical Genetics, Moskvorechye Str. 1, Moscow 115522, Russia.
Dmitry GoldshteinResearch Centre for Medical Genetics, Moskvorechye Str. 1, Moscow 115522, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers constitute a leading cause of mortality. Chimeric antigen receptor (CAR) cell therapies provide breakthrough solutions for various cancers while posing considerable risks of immunological side reactions. Of various cytotoxic lymphocyte subsets, natural killer (NK) cells are considered the least immunogenic. Obtaining viable NK cells with stable phenotypes in quantities sufficient for modification is technologically challenging. The candidate sources include primary mononuclear cell cultures and immortalized NK cell lines; alternatively, the clinical-grade NK cells can be differentiated from induced pluripotent stem cells (iPSCs) by a good manufacturing practice (GMP)-compatible xeno-free protocol. In this review, we analyze existing protocols for targeted differentiation of human iPSCs into NK cells with a focus on xeno-free requirements.

Indexed as

Cell DifferentiationImmunotherapy, AdoptiveInduced Pluripotent Stem CellsKiller Cells, NaturalAnimalsCell Culture TechniquesHumansadoptive NK cell therapyinduced pluripotent stem cellsxeno-free platforms

Identifiers

PMID39940874
PMCPMC11816922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.